Treatment and pharmaceutical care of a case of follicular lymphoma with persistent positive SARS-Cov-2

VernacularTitle:1例滤泡型淋巴瘤患者新型冠状病毒持续阳性的治疗及药学监护
Author: Jie-Qing ZHANG ¹ ; Xiao-Fen YE ; Qian-Zhou LYU ; Xiao-Yu LI ; Shu-Jing CHEN
Author Information

1. 复旦大学附属中山医院药剂科,上海 200032
Keywords: severe pneumonia; SARS-CoV-2; follicular lymphoma; pharmaceutical care
From: Fudan University Journal of Medical Sciences 2024;51(4):632-637,642
CountryChina
Language:Chinese
Abstract: SARS-CoV-2 has posed a significant threat to a subset of the patient population.The occurrence of hematological malignancies and tumor treatment can lead to immunosuppression in patients,which significantly increases the risk of serious complications,severe incidence and mortality after SARS-CoV-2 infection.The treatment of a patient with follicular lymphoma infected with SARS-CoV-2 was described in detail.The patient remained positive for RT-PCR tests during the hospitalization for nearly 90 days.After undergoing 5 rounds of antiviral treatment,along with glucocorticoid anti-inflammatory therapy,low-molecular-weight heparin for anticoagulation,antibiotics for infection control,and respiratory support through the use of a ventilator,the patient eventually obtained negative result of the RT-PCR test.Subsequently,the patient was successfully weaned from mechanical ventilation and discharged.By summarizing the treatment process of this case,we hoped to provide reference and experience for future clinical diagnosis and treatment.